Last reviewed · How we verify
NCT04620655
RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL
NA trial testing RD13-01 cell infusion in T Acute Lymphoblastic Leukemia in 24 participants. Status unknown.
15 November 2021
Quick facts
| Lead sponsor | Min Xiang |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 15 November 2020 |
| Primary completion | 15 November 2021 |
| Estimated completion | 15 November 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- RD13-01 cell infusion — full drug profile →
Conditions studied
- T Acute Lymphoblastic Leukemia — all drugs for T Acute Lymphoblastic Leukemia →
- T-lymphoblastic Lymphoma — all drugs for T-lymphoblastic Lymphoma →
Sponsor
Min Xiang
Who can join
Adults 3 to 70, any sex, with T Acute Lymphoblastic Leukemia or T-lymphoblastic Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is designed to explore the safety of RD13-01 for patients with CD7+ relapsed and/or refractory T cell acute lymphoblastic leukemia or lymphoblastic lymphoma. And to evaluate the efficacy and pharmacokinetics of RD13-01 in patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04620655
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of RD13-01 cell infusion
Trials testing the same drug.
- NCT04538599 — RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies · Phase 1 · completed
Other recruiting trials for T Acute Lymphoblastic Leukemia
Currently open trials in the same condition.
- NCT06738368 — Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombin · Phase 2 · recruiting
- NCT07021677 — Use of a New Medicine "Daratumumab" to Treat Left-over Cancer in a Blood Cancer Called "T Acute Lymphoblastic Leukemia" · Phase 2 · recruiting
- NCT05602194 — Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma · Phase 3 · recruiting
- NCT04128501 — Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting · Phase 2 · active not recruiting
- NCT03007147 — Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positiv · Phase 3 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04620655 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Min Xiang
- Last refreshed: 9 November 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04620655.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing